Table 1 Properties of different nanomaterials in cancer therapy.
From: Nanomedicine-induced programmed cell death in cancer therapy: mechanisms and perspectives
Nanodrugs | Nanomaterials | Cancer cells | Function | Active/passive |
|---|---|---|---|---|
TP-PMs [115] | Polymeric micelles | HT29 | Induce apoptosis | Passive |
TP/Ce6-LP + L [116] | Liposomes | HCC cells | Inhibit HCC progression | Passive |
Apt-NPs-DTX [117] | Polymeric nanoparticle | CT26 | Enhanced CT26 killing CC cells | Passive |
C16-N/T hydrogel [118] | Nanogels | HCC cells | Restrain tumor proliferation | Passive |
TPL@nano-gel [114] | Nanogels | MCF-7and MDA-MB-231 | Inhibit antiangiogenic capacity | Passive |
TP/Curc-NPs [119] | Polymeric nanoparticles | SKOV-3 | Reduce triptolide-induced toxicity | Passive |
PTX/TP-LPN [36] | Polymeric nanoparticles | NSCLC cells | Synergistic effect on lung cancer xenografts | Passive |
TPL/NPs [120] | Polymeric nanoparticles | MCF-7and MDA-MB-231 | Induce apoptosis/ Inhibit the expression of matrix metalloproteinases | Active |
GC-TP-NPs [38] | Polymeric nanoparticles | HCC cells | Block TNF/NF-κB/BCL2 signaling | Active |
Au-Dox [121] | Metallic nanoparticle | Cancer cells | Reduce cancer vitality | Passive |
177Lu-BN-PLGA (PTX) [122] | Polymeric nanoparticles | MDA-MB-231 | Facilitate paclitaxel delivery system | Passive |
DOXs@BSA NPs [27] | Polymeric nanoparticles | Cancer cells | Improve serum stability | Passive |
FEM@PFC [123] | Polymeric nanoparticles | Cancer cells | Immunosuppression and redox balance in TME | Passive |
PPy-Te NPs [37] | Polymeric nanoparticles | Cancer cells | Improve biocompatibility | Passive |
AuNRs@SiO2-RB@MnO2 [34] | Msetallic nanoparticles | Cancer cells | Improve the accuracy of tumor imaging | Passive |
